Form 4: Teladoc Director Sandra Fenwick Receives RSU Grant

Teladoc Health director Sandra Fenwick was granted 30,441 restricted stock units as part of annual director compensation.

Summary

• Director Sandra L. Fenwick received a grant of 30,441 restricted stock units (RSUs) on May 21, 2026.
• Each RSU represents a contingent right to receive one share of Teladoc Health common stock.
• The units vest in full on the earlier of May 21, 2027, or the day before the 2027 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon the vesting and settlement of the units.

Risks

• Market volatility affecting the value of equity compensation.
• Potential for future dilution of common stock.

Future Outlook

The RSUs are scheduled to vest in May 2027, subject to the director's continued service or specific change-in-control provisions.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure board members maintain a vested interest in the company's long-term performance.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for S&P 500 and mid-cap healthcare technology companies.
• Vesting schedules tied to annual meetings are common practice for board-level equity awards.

Corporate Governance

Stakeholder Impact

• Minor dilution impact for shareholders upon future settlement of the units.

Next Steps

• Vesting of the 30,441 RSUs on May 21, 2027, or the day prior to the 2027 annual meeting.

Key Dates

Keywords

Teladoc Health, TDOC, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units